Cancer-associated fibroblast-secreted FGF7 as an ovarian cancer progression promoter.
CAFs
Epithelial-mesenchymal transition
FGF7
FGFR2
Ovarian cancer
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
received:
02
11
2023
accepted:
10
03
2024
medline:
18
3
2024
pubmed:
16
3
2024
entrez:
16
3
2024
Statut:
epublish
Résumé
Ovarian cancer (OC) is distinguished by its aggressive nature and the limited efficacy of current treatment strategies. Recent studies have emphasized the significant role of cancer-associated fibroblasts (CAFs) in OC development and progression. Employing sophisticated machine learning techniques on bulk transcriptomic datasets, we identified fibroblast growth factor 7 (FGF7), derived from CAFs, as a potential oncogenic factor. We investigated the relationship between FGF7 expression and various clinical parameters. A series of in vitro experiments were undertaken to evaluate the effect of CAFs-derived FGF7 on OC cell activities, such as proliferation, migration, and invasion. Single-cell transcriptomic analysis was also conducted to elucidate the interaction between FGF7 and its receptor. Detailed mechanistic investigations sought to clarify the pathways through which FGF7 fosters OC progression. Our findings indicate that higher FGF7 levels correlate with advanced tumor stages, increased vascular invasion, and poorer prognosis. CAFs-derived FGF7 significantly enhanced OC cell proliferation, migration, and invasion. Single-cell analysis and in vitro studies revealed that CAFs-derived FGF7 inhibits the ubiquitination and degradation of hypoxia-inducible factor 1 alpha (HIF-1α) via FGFR2 interaction. Activation of the FGF7/HIF-1α pathway resulted in the upregulation of mesenchymal markers and downregulation of epithelial markers. Importantly, in vivo treatment with neutralizing antibodies targeting CAFs-derived FGF7 substantially reduced tumor growth. Neutralizing FGF7 in the medium or inhibiting HIF-1α signaling reversed the effects of FGF7-mediated EMT, emphasizing the dependence of FGF7-mediated EMT on HIF-1α activation. These findings suggest that targeting the FGF7/HIF-1α/EMT axis may offer new therapeutic opportunities to intervene in OC progression.
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian cancer (OC) is distinguished by its aggressive nature and the limited efficacy of current treatment strategies. Recent studies have emphasized the significant role of cancer-associated fibroblasts (CAFs) in OC development and progression.
METHODS
METHODS
Employing sophisticated machine learning techniques on bulk transcriptomic datasets, we identified fibroblast growth factor 7 (FGF7), derived from CAFs, as a potential oncogenic factor. We investigated the relationship between FGF7 expression and various clinical parameters. A series of in vitro experiments were undertaken to evaluate the effect of CAFs-derived FGF7 on OC cell activities, such as proliferation, migration, and invasion. Single-cell transcriptomic analysis was also conducted to elucidate the interaction between FGF7 and its receptor. Detailed mechanistic investigations sought to clarify the pathways through which FGF7 fosters OC progression.
RESULTS
RESULTS
Our findings indicate that higher FGF7 levels correlate with advanced tumor stages, increased vascular invasion, and poorer prognosis. CAFs-derived FGF7 significantly enhanced OC cell proliferation, migration, and invasion. Single-cell analysis and in vitro studies revealed that CAFs-derived FGF7 inhibits the ubiquitination and degradation of hypoxia-inducible factor 1 alpha (HIF-1α) via FGFR2 interaction. Activation of the FGF7/HIF-1α pathway resulted in the upregulation of mesenchymal markers and downregulation of epithelial markers. Importantly, in vivo treatment with neutralizing antibodies targeting CAFs-derived FGF7 substantially reduced tumor growth.
CONCLUSION
CONCLUSIONS
Neutralizing FGF7 in the medium or inhibiting HIF-1α signaling reversed the effects of FGF7-mediated EMT, emphasizing the dependence of FGF7-mediated EMT on HIF-1α activation. These findings suggest that targeting the FGF7/HIF-1α/EMT axis may offer new therapeutic opportunities to intervene in OC progression.
Identifiants
pubmed: 38491511
doi: 10.1186/s12967-024-05085-y
pii: 10.1186/s12967-024-05085-y
pmc: PMC10941588
doi:
Substances chimiques
Fibroblast Growth Factor 7
126469-10-1
Hypoxia-Inducible Factor 1, alpha Subunit
0
FGF7 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
280Informations de copyright
© 2024. The Author(s).
Références
J Biol Chem. 2006 Jun 9;281(23):15694-700
pubmed: 16597617
Nat Rev Drug Discov. 2009 Mar;8(3):235-53
pubmed: 19247306
Oncogene. 2020 Oct;39(43):6647-6663
pubmed: 32934314
Cell Death Dis. 2019 Mar 20;10(4):273
pubmed: 30894509
Eur J Surg Oncol. 2021 Aug;47(8):2206
pubmed: 33895026
Curr Probl Cardiol. 2023 Feb;48(2):101464
pubmed: 36261105
Nat Rev Genet. 2009 Jan;10(1):57-63
pubmed: 19015660
J Oncol. 2022 Jun 22;2022:7020774
pubmed: 35783154
Nat Commun. 2022 Apr 19;13(1):2104
pubmed: 35440541
Front Genet. 2019 Feb 12;10:102
pubmed: 30809251
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
PLoS One. 2021 Apr 8;16(4):e0245376
pubmed: 33831027
Cell Death Dis. 2022 Aug 4;13(8):675
pubmed: 35927239
Adv Sci (Weinh). 2022 Aug;9(22):e2202260
pubmed: 35618488
Mech Dev. 1994 Jan;45(1):15-30
pubmed: 8186145
Methods Mol Biol. 2016;1418:111-41
pubmed: 27008012
Nat Rev Immunol. 2010 Aug;10(8):554-67
pubmed: 20616810
J Insur Med. 2017;47(1):31-39
pubmed: 28836909
Bioinformatics. 2011 Jan 1;27(1):87-94
pubmed: 21062763
Biosci Rep. 2017 Apr 10;37(2):
pubmed: 28258248
Cancer Manag Res. 2019 Jul 01;11:5983-6001
pubmed: 31308741
Clin Cancer Res. 2022 Aug 15;28(16):3590-3602
pubmed: 35675036
Clin Cancer Res. 2021 May 1;27(9):2636-2647
pubmed: 33622705
Science. 1989 Aug 18;245(4919):752-5
pubmed: 2475908
Mol Oncol. 2022 Mar;16(6):1272-1289
pubmed: 34850536
Oncogene. 2022 May;41(20):2885-2896
pubmed: 35428876
Nat Methods. 2019 Dec;16(12):1289-1296
pubmed: 31740819
Clin Cancer Res. 2011 May 1;17(9):2842-51
pubmed: 21367751
Bioinformatics. 2009 Apr 1;25(7):890-6
pubmed: 19244389
J Pathol. 2019 Oct;249(2):193-205
pubmed: 31090071
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
Proc Math Phys Eng Sci. 2014 Jul 8;470(2167):20140081
pubmed: 25002826
Nat Commun. 2021 Feb 17;12(1):1088
pubmed: 33597522
Nat Cell Biol. 2017 May;19(5):518-529
pubmed: 28414315
Front Immunol. 2021 Jul 02;12:687975
pubmed: 34276676
Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5
pubmed: 23193258
BMC Bioinformatics. 2010 Jun 02;11:296
pubmed: 20525176
iScience. 2022 Jan 22;25(2):103798
pubmed: 35169688
Sci China C Life Sci. 2008 Aug;51(8):711-7
pubmed: 18677599
Comput Struct Biotechnol J. 2021 Jun 22;19:3735-3746
pubmed: 34285775
Nat Commun. 2022 Feb 10;13(1):816
pubmed: 35145098
Front Immunol. 2022 Jul 08;13:951582
pubmed: 35874760
Lifetime Data Anal. 2008 Jun;14(2):179-95
pubmed: 18188699
J Cell Biochem. 2019 Mar;120(3):2782-2790
pubmed: 30321449
J Exp Med. 2019 Mar 4;216(3):688-703
pubmed: 30710055
Gene. 2021 Sep 25;798:145796
pubmed: 34175393
J Urol. 2015 Jul;194(1):223-9
pubmed: 25623741
Cancer Immunol Immunother. 2023 Jul;72(7):2423-2442
pubmed: 37010552
Oncol Lett. 2021 Aug;22(2):599
pubmed: 34188701
Liver Int. 2023 Aug;43(8):1729-1740
pubmed: 37183518
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Mediators Inflamm. 2023 Apr 25;2023:3781091
pubmed: 37144239
PLoS One. 2015 Jun 09;10(6):e0129603
pubmed: 26057751
Front Oncol. 2023 Feb 22;13:1084523
pubmed: 36910623
Signal Transduct Target Ther. 2023 Feb 17;8(1):70
pubmed: 36797231
Biotechnol Adv. 2021 Jul-Aug;49:107739
pubmed: 33794304
J Clin Invest. 2013 Sep;123(9):3664-71
pubmed: 23999440
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Mol Oncol. 2022 Aug;16(15):2823-2842
pubmed: 35726195
J Biopharm Stat. 2010 Mar;20(2):281-300
pubmed: 20309759
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Invest. 2012 Oct;122(10):3603-17
pubmed: 22945634
Br J Haematol. 2002 Mar;116(3):505-10
pubmed: 11849205
Cancers (Basel). 2022 May 26;14(11):
pubmed: 35681617
Cancer Med. 2019 Dec;8(18):7822-7832
pubmed: 31674718
Nature. 2019 May;569(7758):723-728
pubmed: 31043742